Cargando…
Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
Advancements and the use of tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of Chronic Myeloid Leukemia (CML), achieving unprecedented success rates and expanding their applications to various neoplasms. However, the use of TKIs is not without its drawbacks. Skin, gastrointestina...
Autores principales: | Yakobson, Alexander, Neime, Ala Eddin, Abu Saleh, Omar, Al Athamen, Kayed, Shalata, Walid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514788/ https://www.ncbi.nlm.nih.gov/pubmed/37736932 http://dx.doi.org/10.3390/clinpract13050096 |
Ejemplares similares
-
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2022) -
Bullous pemphigoid
por: Miyamoto, Denise, et al.
Publicado: (2019) -
Bullous Pemphigoid and Other Pemphigoid Dermatoses
por: Pratasava, Valeryia, et al.
Publicado: (2021) -
Linagliptin-Associated Alopecia and Bullous Pemphigoid
por: Someili, Ali, et al.
Publicado: (2019) -
Resolution in bullous pemphigoid
por: Sadik, Christian D., et al.
Publicado: (2019)